Pseudo–Pelger-Huët Anomaly Induced by Medications

Endi Wang(University of Southern California), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Elizabeth Boswell(Duke Medical Center), Chuanyi M. Lu(San Francisco VA Health Care System), Siby Sebastian(Duke University), Imran Siddiqi(University of Southern California), Catherine Rehder(Duke University)

American Journal of Clinical Pathology

January 12, 2011

10.1309/ajcpvfy95maobkrs

Cited by 55

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.

|Journal of Biological Chemistry|1993|375

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

|Proceedings of the National Academy of Sciences|2013|297